GLP-1s

HHS said it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound drugs using six unapproved peptides, as long as they meet a set of conditions, according to an interim policy scheduled…

Walgreens is expanding its GLP-1 services with insurance navigation, prior authorization support and pharmacist follow-up for patients starting treatment. Through Walgreens Weight Management, eligible patients can connect virtually with a physician or nurse practitioner and receive a prescription for an…

A case report from researchers at the University of Colorado Anschutz Medical Campus in Aurora links tirzepatide, sold as Zepbound, to lithium toxicity in a 50-year-old woman with bipolar disorder. It is the fourth reported case of tirzepatide-associated lithium toxicity,…

The evidence on GLP-1s and pregnancy has grown from social media anecdotes to formal clinical guidance in three years. Here are six notes on how it changed.

Patients who stop taking GLP-1s for pregnancy may be able to resume them while breastfeeding, according to an advisory from the American College of Obstetricians and Gynecologists published Oct. 23. Under the guidance, OB-GYNs and other healthcare professionals can work…

The White House is reviewing a proposal to broaden access to compounded peptides with more patient protections than initially expected, according to an Oct. 22 Bloomberg report. Here are five things to know:

Apothecary Pharma is recalling 22 vials of compounded tirzepatide injection nationwide over a lack of assurance of sterility, according to an Oct. 8 FDA notice. Here are four things to know:

Patients taking GLP-1 medications had lower rates of major cardiovascular complications and infections after surgery than those not taking the drugs, according to a study of more than 2 million adults presented Oct. 18 at the American Society of Anesthesiologists’…

HHS has submitted a peptide “interim access policy” to the White House Office of Management and Budget for review, according to a listing on OMB’s regulatory review site. Here are five things to know:

An Oct. 13 analysis from the Health Transformation Alliance examined linked claims and EHR data for 12.7 million patients from 2018 through 2025 to identify who is most and least likely to respond to GLP-1 therapy. Here are six things…